Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Edwards Lifesciences Corporation has received an average recommendation of “Moderate Buy” from 26 analysts, with target prices ranging from $75.00 to $100.00.
• In its latest earnings report, the company achieved an earnings per share of $0.67, exceeding analysts' expectations and indicating an 11.9% revenue increase year-over-year.
• Insider selling activity included VP Daniel J. Lippis offloading 4,114 shares, reducing his position by 15.75%, amidst increased institutional interest in the company.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty-six analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and three have assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $85.9048.

EW has been the topic of a number of research reports. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a report on Friday, July 25th. BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price on the stock in a report on Tuesday, July 29th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Wall Street Zen raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Stifel Nicolaus upped their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a research note on Friday, July 25th.

Edwards Lifesciences Trading Down 0.3%

EW opened at $81.1580 on Friday. Edwards Lifesciences has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a market capitalization of $47.65 billion, a price-to-earnings ratio of 11.68, a PEG ratio of 3.93 and a beta of 1.08. The company's 50 day moving average price is $77.45 and its two-hundred day moving average price is $74.60.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the firm posted $0.70 EPS. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Activity

In other news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the completion of the sale, the vice president directly owned 50,356 shares in the company, valued at approximately $3,897,554.40. This represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,584 shares of company stock valued at $1,897,762. 1.29% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. B. Riley Wealth Advisors Inc. bought a new position in Edwards Lifesciences during the second quarter worth $319,000. Marex Group plc bought a new position in Edwards Lifesciences during the second quarter worth $474,000. State of Wyoming boosted its stake in Edwards Lifesciences by 158.7% during the second quarter. State of Wyoming now owns 6,924 shares of the medical research company's stock worth $542,000 after acquiring an additional 4,248 shares in the last quarter. Hudson Bay Capital Management LP bought a new position in Edwards Lifesciences during the second quarter worth $73,083,000. Finally, Geneos Wealth Management Inc. boosted its stake in Edwards Lifesciences by 6.4% during the second quarter. Geneos Wealth Management Inc. now owns 7,939 shares of the medical research company's stock worth $621,000 after acquiring an additional 476 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.